Cover Image
市場調查報告書

呼吸道融合瘤病毒 (RSV) 感染症:開發中產品分析

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229776
出版日期 內容資訊 英文 267 Pages
訂單完成後即時交付
價格
Back to Top
呼吸道融合瘤病毒 (RSV) 感染症:開發中產品分析 Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2016
出版日期: 2016年11月09日 內容資訊: 英文 267 Pages
簡介

呼吸道融合瘤病毒(RSV)感染症是肺與呼吸道受到影響所引起的細氣管支發炎,不滿一歲的嬰兒容易引發肺炎。症狀有咳嗽,鼻塞,鼻涕,喉嚨疼痛,耳痛,發燒等。治療方法為服用恰當的藥,注意衛生狀態。

本報告提供呼吸道融合瘤病毒 (RSV) 感染症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,再加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

呼吸道融合瘤病毒 (RSV) 感染症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

呼吸道融合瘤病毒 (RSV) 感染症:企業開發中的治療藥

呼吸道融合瘤病毒 (RSV) 感染症:大學/機關研究中的治療藥

呼吸道融合瘤病毒 (RSV) 感染症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

呼吸道融合瘤病毒 (RSV) 感染症:企業開發中的產品

呼吸道融合瘤病毒 (RSV) 感染症:大學/機關研究中的產品

呼吸道融合瘤病毒 (RSV) 感染症的治療藥的開發企業

  • Ablynx NV
  • ADMA Biologics, Inc.
  • Agilvax, Inc.
  • Aridis Pharmaceuticals LLC
  • Artificial Cell Technologies, Inc.
  • AstraZeneca Plc
  • Aviragen Therapeutics, Inc.
  • Bavarian Nordic A/S
  • Celltrion, Inc.
  • Codagenix, Inc.
  • CureVac GmbH
  • DBV Technologies S.A.
  • Emergent BioSolutions Inc.
  • Enanta Pharmaceuticals, Inc.
  • Evec, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GenVec, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline Plc
  • Globavir Biosciences, Inc.
  • Humabs BioMed SA
  • iBio, Inc.
  • ILiAD Biotechnologies, LLC
  • Ilyang Pharmaceutical Co., Ltd
  • Immunovaccine, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Kineta, Inc.
  • mAbxience S.A.
  • MedImmune, LLC
  • Medivir AB
  • Merck & Co., Inc.
  • Mucosis B.V.
  • NanoBio Corporation
  • Navigen Pharmaceuticals, Inc.
  • Novavax, Inc.
  • Panacea Biotec Limited
  • Profectus BioSciences, Inc.
  • Pulmocide Ltd
  • Regeneron Pharmaceuticals, Inc.
  • Romark Laboratories, L.C.
  • Sirnaomics, Inc.
  • Spider Biotech
  • Spring Bank Pharmaceuticals, Inc.
  • 武田藥品工業
  • TechnoVax, Inc.
  • The International Biotechnology Center (IBC) Generium
  • Trellis Bioscience, Inc.
  • Vault Pharma Inc.
  • Vaxart, Inc.
  • VaxInnate Corporation
  • VBI Vaccines Inc.
  • Virometix AG
  • Visterra, Inc.
  • VLP Biotech, Inc.

呼吸道融合瘤病毒 (RSV) 感染症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

呼吸道融合瘤病毒 (RSV) 感染症:最近的開發平台趨勢

呼吸道融合瘤病毒 (RSV) 感染症:暫停中的計劃

呼吸道融合瘤病毒 (RSV) 感染症:開發中止的產品

呼吸道融合瘤病毒 (RSV) 感染症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8671IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2016, provides an overview of the Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline landscape.

Respiratory syncytial virus (RSV) infection is a respiratory disease. It infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache and fever. Treatment includes proper medication and hygiene practice.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 12, 11, 50 and 14 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 4, 13 and 4 molecules, respectively.Respiratory Syncytial Virus (RSV) Infections.

Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Respiratory Syncytial Virus (RSV) Infections Overview
  • Therapeutics Development
  • Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Development by Companies
  • Respiratory Syncytial Virus (RSV) Infections - Therapeutics under Investigation by Universities/Institutes
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline Products Glance
  • Respiratory Syncytial Virus (RSV) Infections - Products under Development by Companies
  • Respiratory Syncytial Virus (RSV) Infections - Products under Investigation by Universities/Institutes
  • Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development
  • Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment
  • Drug Profiles
  • Respiratory Syncytial Virus (RSV) Infections - Dormant Projects
  • Respiratory Syncytial Virus (RSV) Infections - Discontinued Products
  • Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2016
  • Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Abivax SA, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ablynx NV, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by ADMA Biologics, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Agilvax, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Artificial Cell Technologies, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by AstraZeneca Plc, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aviragen Therapeutics, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Bavarian Nordic A/S, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Celltrion, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Codagenix, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Curevac AG, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by DBV Technologies S.A., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Emergent BioSolutions Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Enanta Pharmaceuticals, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Evec, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gene Techno Science Co., Ltd., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by GenVec, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gilead Sciences, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Globavir Biosciences, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Humabs BioMed SA, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by iBio, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by ILiAD Biotechnologies, LLC, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ilyang Pharmaceutical Co., Ltd, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Immunovaccine Inc, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Johnson & Johnson, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Kineta, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by mAbxience S.A., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by MedImmune LLC, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Medivir AB, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Merck & Co., Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mucosis B.V., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mymetics Corporation, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by NanoBio Corporation, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Navigen Pharmaceuticals, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by NeuClone Pty Ltd, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Novavax, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Panacea Biotec Limited, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Profectus BioSciences, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Pulmocide Ltd, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Romark Laboratories, L.C., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spider Biotech, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by TechnoVax, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Themis Bioscience GmbH, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Trellis Bioscience, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vault Pharma Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vaxart Inc, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by VaxInnate Corporation, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by VBI Vaccines Inc, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Virometix AG, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by Visterra, Inc., H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Pipeline by VLP Biotech, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..1), H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..2), H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..3), H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Dormant Projects (Contd..4), H2 2016
  • Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2016
  • Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top